WEBULL
News
BEIGF
28.45
NaN%
--
Tracking Baker Brothers Portfolio - Q3 2025 Update
Seeking Alpha · 12/16 14:19
Zymeworks shifts to a royalty-driven business model
Seeking Alpha · 11/18 17:24
Jazz, Zymeworks’ Ziihera trial shows significant PFS improvement, shares rally
Seeking Alpha · 11/17 12:13
Saudi sovereign wealth fund cuts holdings of U.S. stocks
Seeking Alpha · 11/16 14:16
BeOne Medicines outlines $5.1B–$5.3B 2025 revenue target amid BRUKINSA momentum and expanding pipeline
Seeking Alpha · 11/06 20:17
BeOne Medicines: Sonrotoclax Could Set Next Stage Of Growth For Hematology Pipeline
Seeking Alpha · 10/14 20:24
BeOne Medicines' sonrotoclax gets FDA breakthrough therapy status
Seeking Alpha · 10/13 13:08
Tracking Baker Brothers Portfolio - Q2 2025 Update
Seeking Alpha · 09/16 00:21
Weekly Report: what happened at BEIGF last week (0908-0912)?
Weekly Report · 09/15 10:19
Bristol-Myers Squibb: Why Q2 Results Signal A Turning Point
Seeking Alpha · 09/08 13:47
Weekly Report: what happened at BEIGF last week (0901-0905)?
Weekly Report · 09/08 10:21
Weekly Report: what happened at BEIGF last week (0825-0829)?
Weekly Report · 09/01 10:17
AbbVie Smashes Earnings, Bets Big On Depression Drug Bretisilocin
Seeking Alpha · 08/29 16:37
Weekly Report: what happened at BEIGF last week (0818-0822)?
Weekly Report · 08/25 10:24
Weekly Report: what happened at BEIGF last week (0811-0815)?
Weekly Report · 08/18 10:19
Artisan International Small-Mid Fund Q2 2025 Commentary
Seeking Alpha · 08/14 02:30
Weekly Report: what happened at BEIGF last week (0804-0808)?
Weekly Report · 08/11 10:23
BeOne Medicines outlines $5B–$5.3B 2025 revenue target as BRUKINSA leads BTK market and global expansion accelerates
Seeking Alpha · 08/06 17:37
BeOne Medicines Ltd. Non-GAAP EPS of ADS2.25, revenue of ADS1.3B
Seeking Alpha · 08/06 11:58
BeOne Medicines beats top-line and bottom-line estimates; updates FY guidance
Seeking Alpha · 08/06 11:52
More
Webull provides a variety of real-time BEIGF stock news. You can receive the latest news about Beigene through multiple platforms. This information may help you make smarter investment decisions.
About BEIGF
BeOne Medicines AG, formerly BeiGene, Ltd., is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. Its products include Brukinsa, Tevimbra and Pamiparib. Brukinsa is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Tevimbra is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is designed to minimize binding to Fc-gamma (Fcy) receptors on macrophages, helping the body’s immune cells detect and fight tumors. The Company’s product pipeline in development includes Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, BG-68501, BG-C9074, BGB-43395, Xaluritamig, and others.